Compare Stocks: TMDX, GMED, GKOS, and PODD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GKOS Glaukos	$184.43 -0.1%	$151.24	$73.16 ▼ $190.00	$10.88B	0.78	877,061 shs	313,814 shs
GMED Globus Medical	$85.20 -0.8%	$79.98	$54.15 ▼ $101.40	$11.44B	0.95	1.50 million shs	535,096 shs
PODD Insulet	$140.09 -2.3%	$155.20	$126.40 ▼ $354.88	$9.72B	1.1	1.31 million shs	1.09 million shs
TMDX TransMedics Group	$87.78 -0.9%	$75.65	$60.10 ▼ $156.00	$3.03B	1.9	1.07 million shs	234,349 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GKOS Glaukos	0.00%	+2.65%	+17.86%	+29.89%	+105.75%
GMED Globus Medical	0.00%	+4.31%	+11.35%	+8.61%	+41.43%
PODD Insulet	0.00%	+1.54%	-12.63%	-6.00%	-55.38%
TMDX TransMedics Group	0.00%	+5.59%	+19.74%	+29.62%	-30.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GKOS Glaukos	$184.43 -0.1%	$151.24	$73.16 ▼ $190.00	$10.88B	0.78	877,061 shs	313,814 shs
GMED Globus Medical	$85.20 -0.8%	$79.98	$54.15 ▼ $101.40	$11.44B	0.95	1.50 million shs	535,096 shs
PODD Insulet	$140.09 -2.3%	$155.20	$126.40 ▼ $354.88	$9.72B	1.1	1.31 million shs	1.09 million shs
TMDX TransMedics Group	$87.78 -0.9%	$75.65	$60.10 ▼ $156.00	$3.03B	1.9	1.07 million shs	234,349 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GKOS Glaukos	0.00%	+2.65%	+17.86%	+29.89%	+105.75%
GMED Globus Medical	0.00%	+4.31%	+11.35%	+8.61%	+41.43%
PODD Insulet	0.00%	+1.54%	-12.63%	-6.00%	-55.38%
TMDX TransMedics Group	0.00%	+5.59%	+19.74%	+29.62%	-30.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GKOS Glaukos	2.79	Moderate Buy	$177.33	-4.47% Downside
GMED Globus Medical	2.88	Moderate Buy	$101.77	19.45% Upside
PODD Insulet	2.44	Hold	$195.40	38.40% Upside
TMDX TransMedics Group	2.38	Hold	$124.18	40.60% Upside

Current Analyst Ratings Breakdown

Latest TMDX, GMED, GKOS, and PODD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	GMED Globus Medical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	GMED Globus Medical	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$103.00 ➝ $99.00
8/6/2026	PODD Insulet	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$175.00
8/6/2026	PODD Insulet	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$200.00 ➝ $175.00
8/6/2026	PODD Insulet	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$245.00 ➝ $160.00
8/6/2026	PODD Insulet	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/6/2026	PODD Insulet	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$180.00
8/6/2026	PODD Insulet	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$249.00 ➝ $179.00
8/6/2026	PODD Insulet	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$294.00 ➝ $144.00
8/6/2026	PODD Insulet	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$174.00 ➝ $150.00
8/6/2026	PODD Insulet	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$250.00 ➝ $185.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GKOS Glaukos	$507.44M	21.58	N/A	N/A	$11.42 per share	16.26
GMED Globus Medical	$3.14B	3.64	$6.23 per share	13.67	$33.86 per share	2.52
PODD Insulet	$2.71B	3.62	$6.23 per share	22.67	$21.54 per share	6.55
TMDX TransMedics Group	$605.49M	5.04	$3.91 per share	22.56	$13.79 per share	6.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GKOS Glaukos	-$187.69M	-$3.25	N/A	378.85	N/A	-30.68%	-6.37%	-4.78%	11/4/2026 (Estimated)
GMED Globus Medical	$537.87M	$3.91	21.80	16.04	1.38	17.02%	14.57%	12.62%	11/5/2026 (Estimated)
PODD Insulet	$247.10M	$5.35	26.37	18.34	1.13	12.29%	29.29%	13.31%	11/5/2026 (Estimated)
TMDX TransMedics Group	$190.29M	$3.89	22.65	38.07	N/A	22.69%	15.88%	5.95%	11/4/2026 (Estimated)

Latest TMDX, GMED, GKOS, and PODD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	GMED Globus Medical	$1.10	$1.34	+$0.24	$1.10	$782.88 million	$789.61 million
8/5/2026	Q2 2026	PODD Insulet	$1.47	$1.66	+$0.19	$1.37	$787.39 million	$801.70 million
8/4/2026	Q2 2026	TMDX TransMedics Group	$0.4955	$0.44	-$0.0555	$0.41	$184.00 million	$189.95 million
7/29/2026	Q2 2026	GKOS Glaukos	-$0.2105	-$0.14	+$0.0705	-$0.31	$150.93 million	$185.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
GMED Globus Medical	N/A	N/A	N/A	N/A	N/A
PODD Insulet	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GKOS Glaukos	0.10	5.04	4.46
GMED Globus Medical	N/A	4.62	2.93
PODD Insulet	0.65	2.48	1.83
TMDX TransMedics Group	1.62	6.62	6.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GKOS Glaukos	99.04%
GMED Globus Medical	95.16%
PODD Insulet	N/A
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
GKOS Glaukos	5.90%
GMED Globus Medical	18.38%
PODD Insulet	0.36%
TMDX TransMedics Group	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GKOS Glaukos	1,094	58.98 million	55.50 million	Optionable
GMED Globus Medical	6,000	134.26 million	109.59 million	Optionable
PODD Insulet	5,400	69.35 million	69.10 million	Optionable
TMDX TransMedics Group	210	34.56 million	32.18 million	Optionable

TMDX, GMED, GKOS, and PODD Headlines

Recent News About These Companies

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

3 hours ago | businesswire.com

TransMedics Group, Inc. $TMDX Shares Sold by Royal Bank of Canada

August 17 at 4:39 AM | marketbeat.com

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

August 17 at 3:00 AM | prnewswire.com

TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of "Hold" by Brokerages

August 16 at 2:28 AM | americanbankingnews.com

TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Hold" from Brokerages

August 16 at 2:28 AM | marketbeat.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

August 13, 2026 | globenewswire.com

Wasatch Advisors LP Has $20.49 Million Stock Position in TransMedics Group, Inc. $TMDX

August 13, 2026 | marketbeat.com

TransMedics (TMDX) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

TransMedics Group, Inc. (TMDX) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

August 11, 2026 | seekingalpha.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

August 11, 2026 | prnewswire.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

August 8, 2026 | globenewswire.com

Piper Sandler Reaffirms Overweight Rating for TransMedics Group (NASDAQ:TMDX)

August 7, 2026 | americanbankingnews.com

TransMedics Group (NASDAQ:TMDX) Shares Gap Down Following Weak Earnings

August 7, 2026 | americanbankingnews.com

TransMedics: Margins Down, Concentration Up, Trials Delayed

August 6, 2026 | seekingalpha.com

TransMedics outlines $737M-$757M 2026 revenue outlook while targeting 30,000 transplants by 2032

August 5, 2026 | seekingalpha.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

August 5, 2026 | prnewswire.com

Piper Sandler Keeps Their Buy Rating on TransMedics Group (TMDX)

August 5, 2026 | theglobeandmail.com

TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $77.00 at UBS Group

August 5, 2026 | marketbeat.com

TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract

August 5, 2026 | zacks.com

TransMedics Group (NASDAQ:TMDX) Earns "Overweight" Rating from Piper Sandler

August 5, 2026 | marketbeat.com

TransMedics Group (NASDAQ:TMDX) Shares Gap Down on Disappointing Earnings

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TMDX, GMED, GKOS, and PODD Company Descriptions

Glaukos NYSE:GKOS

$184.43 -0.10 (-0.05%)

As of 02:21 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Globus Medical NYSE:GMED

$85.20 -0.70 (-0.81%)

As of 02:21 PM Eastern

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Insulet NASDAQ:PODD

$140.09 -3.25 (-2.27%)

As of 02:21 PM Eastern

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

TransMedics Group NASDAQ:TMDX

$87.78 -0.80 (-0.90%)

As of 02:20 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TMDX, GMED, GKOS, and PODD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TMDX, GMED, GKOS, and PODD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TMDX, GMED, GKOS, and PODD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TMDX, GMED, GKOS, and PODD Company Descriptions

Glaukos NYSE:GKOS

Globus Medical NYSE:GMED

Insulet NASDAQ:PODD

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TMDX, GMED, GKOS, and PODD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TMDX, GMED, GKOS, and PODD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TMDX, GMED, GKOS, and PODD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TMDX, GMED, GKOS, and PODD Company Descriptions

Glaukos NYSE:GKOS

Globus Medical NYSE:GMED

Insulet NASDAQ:PODD

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools